{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:35:24Z","timestamp":1792496124632,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00520-025-09952-2","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T06:19:25Z","timestamp":1759817965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review"],"prefix":"10.1007","volume":"33","author":[{"given":"Maria T.","family":"Cruz Carreras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gonz\u00e1lez Landr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Padr\u00f3n Alc\u00e1ntara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Markides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Chaftari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"9952_CR1","doi-asserted-by":"publisher","first-page":"251513552311920","DOI":"10.1177\/25151355231192043","volume":"11","author":"AN Kamali","year":"2023","unstructured":"Kamali AN, Bautista JM, Eisenhut M, Hamedifar H (2023) Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands. Ther Adv Vaccines Immunother 11:25151355231192044. https:\/\/doi.org\/10.1177\/25151355231192043","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"25","key":"9952_CR2","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C (2022) Hematologic complications of immune checkpoint inhibitors. Blood 139(25):3594\u20133604. https:\/\/doi.org\/10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"9952_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coi.2021.02.002","volume":"69","author":"AL Perdigoto","year":"2021","unstructured":"Perdigoto AL, Kluger H, Herold KC (2021) Adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol 69:29\u201338. https:\/\/doi.org\/10.1016\/j.coi.2021.02.002","journal-title":"Curr Opin Immunol"},{"key":"9952_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","volume":"147","author":"R Kramer","year":"2021","unstructured":"Kramer R, Zaremba A, Moreira A et al (2021) Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer 147:170\u2013181. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.013","journal-title":"Eur J Cancer"},{"issue":"4","key":"9952_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.6004\/jadpro.2021.12.4.4","volume":"12","author":"BB Rogers","year":"2021","unstructured":"Rogers BB, Zawislak C, Wong V (2021) Management of hematologic adverse events associated with immune checkpoint inhibitors. J Adv Pract Oncol 12(4):392\u2013404. https:\/\/doi.org\/10.6004\/jadpro.2021.12.4.4","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"9952_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13187","volume":"102","author":"GE Tanios","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R (2019) Autoimmune hemolytic anemia associated with immune checkpoint inhibitors: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102(2):157\u2013162. https:\/\/doi.org\/10.1111\/ejh.13187","journal-title":"Eur J Haematol"},{"issue":"2","key":"9952_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.hoc.2021.11.002","volume":"36","author":"SR Hwang","year":"2022","unstructured":"Hwang SR, Saliba AN, Wolanskyj-Spinner AP (2022) Immunotherapy-associated autoimmune hemolytic anemia. Hematol Oncol Clin North Am 36(2):365\u2013380. https:\/\/doi.org\/10.1016\/j.hoc.2021.11.002","journal-title":"Hematol Oncol Clin North Am"},{"issue":"36","key":"9952_CR8","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"9952_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-132203","author":"K Gnanapandithan","year":"2019","unstructured":"Gnanapandithan K, Kharel P, Grimshaw A, Giri S (2019) Hematologic immune-related adverse events from immune checkpoint inhibitors: a systematic review of case-reports and case-series. Blood. https:\/\/doi.org\/10.1182\/blood-2019-132203","journal-title":"Blood"},{"issue":"5","key":"9952_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem JE, Young A et al (2019) Hematologic complications of immune checkpoint inhibitors. Oncologist 24(5):584\u2013588. https:\/\/doi.org\/10.1634\/theoncologist.2018-0574","journal-title":"Oncologist"},{"issue":"4","key":"9952_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood.2020005674","volume":"136","author":"S Berentsen","year":"2020","unstructured":"Berentsen S, Barcellini W, D\u2019Sa S et al (2020) Cold agglutinin disease revisited: a multinational observational study of 232 patients. Blood 136(4):480\u2013488. https:\/\/doi.org\/10.1182\/blood.2020005674","journal-title":"Blood"},{"issue":"3","key":"9952_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.hoc.2015.01.002","volume":"29","author":"S Berentsen","year":"2015","unstructured":"Berentsen S, Randen U, Tj\u00f8nnfjord GE (2015) Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol Oncol Clin North Am 29(3):455\u2013471. https:\/\/doi.org\/10.1016\/j.hoc.2015.01.002","journal-title":"Hematol Oncol Clin North Am"},{"issue":"19","key":"9952_CR13","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","volume":"124","author":"W Barcellini","year":"2014","unstructured":"Barcellini W, Fattizzo B, Zaninoni A et al (2014) Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 124(19):2930\u20132936. https:\/\/doi.org\/10.1182\/blood-2014-06-583021","journal-title":"Blood"},{"issue":"4","key":"9952_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","volume":"142","author":"K Sawada","year":"2008","unstructured":"Sawada K, Fujishima N, Hirokawa M (2008) Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142(4):505\u2013514. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07216.x","journal-title":"Br J Haematol"},{"issue":"3","key":"9952_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.amjms.2023.06.009","volume":"366","author":"RT Means Jr.","year":"2023","unstructured":"Means RT Jr. (2023) Pure red cell aplasia: the second hundred years. Am J Med Sci 366(3):160\u2013166. https:\/\/doi.org\/10.1016\/j.amjms.2023.06.009","journal-title":"Am J Med Sci"},{"issue":"6","key":"9952_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/CMR.0000000000000392","volume":"27","author":"A Yuki","year":"2017","unstructured":"Yuki A, Takenouchi T, Takatsuka S, Ishiguro T (2017) A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma. Melanoma Res 27(6):635\u2013637. https:\/\/doi.org\/10.1097\/CMR.0000000000000392","journal-title":"Melanoma Res"},{"key":"9952_CR17","doi-asserted-by":"publisher","first-page":"109490","DOI":"10.1016\/j.intimp.2022.109490","volume":"114","author":"Q Guo","year":"2023","unstructured":"Guo Q, Gao J, Guo H, Xie J, Cheng J (2023) Immune checkpoint inhibitor-induced pure red cell aplasia: case series and large-scale pharmacovigilance analysis. Int Immunopharmacol 114:109490. https:\/\/doi.org\/10.1016\/j.intimp.2022.109490","journal-title":"Int Immunopharmacol"},{"issue":"8565","key":"9952_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(87)91432-2","volume":"2","author":"C Rozman","year":"1987","unstructured":"Rozman C, Mar\u00edn P, Nomdedeu B, Montserrat E (1987) Criteria for severe aplastic anaemia. Lancet 2(8565):955\u2013957. https:\/\/doi.org\/10.1016\/S0140-6736(87)91432-2","journal-title":"Lancet"},{"issue":"12","key":"9952_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-017-0511-z","volume":"18","author":"SA Peslak","year":"2017","unstructured":"Peslak SA, Olson T, Babushok DV (2017) Diagnosis and treatment of aplastic anemia. Curr Treat Options Oncol 18(12):70. https:\/\/doi.org\/10.1007\/s11864-017-0511-z","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"9952_CR20","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood.V87.6.2162.bloodjournal8762162","volume":"87","author":"WS Alexander","year":"1996","unstructured":"Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D (1996) Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87(6):2162\u20132170","journal-title":"Blood"},{"issue":"3","key":"9952_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1073\/pnas.95.3.1195","volume":"95","author":"S Kimura","year":"1998","unstructured":"Kimura S, Roberts AW, Metcalf D, Alexander WS (1998) Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A 95(3):1195\u20131200. https:\/\/doi.org\/10.1073\/pnas.95.3.1195","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"9952_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2002-04-1134","volume":"101","author":"N Frickhofen","year":"2003","unstructured":"Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study Group (2003) Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101(4):1236\u20131242. https:\/\/doi.org\/10.1182\/blood-2002-04-1134","journal-title":"Blood"},{"issue":"1","key":"9952_CR23","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48\u2013e57. https:\/\/doi.org\/10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"issue":"7","key":"9952_CR24","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s00277-025-06482-z","volume":"104","author":"Y Li","year":"2025","unstructured":"Li Y, Jiang H, Luo L, Mei H (2025) Immunotherapy-associated hemostatic abnormalities. Ann Hematol 104(7):3537\u20133551. https:\/\/doi.org\/10.1007\/s00277-025-06482-z","journal-title":"Ann Hematol"},{"issue":"49","key":"9952_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031851","volume":"101","author":"H Zhu","year":"2022","unstructured":"Zhu H, Liu JY (2022) Thrombotic thrombocytopenic purpura with neurological impairment: a review. Medicine (Baltimore) 101(49):e31851. https:\/\/doi.org\/10.1097\/MD.0000000000031851","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"9952_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/2324709616661835","volume":"4","author":"M Ban-Hoefen","year":"2016","unstructured":"Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D (2016) Ipilimumab-induced neutropenia in melanoma. J Investig Med High Impact Case Rep 4(3):2324709616661835. https:\/\/doi.org\/10.1177\/2324709616661835","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"6","key":"9952_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/CJI.0000000000000041","volume":"37","author":"P du Rusquec","year":"2014","unstructured":"du Rusquec P, Saint-Jean M, Brocard A et al (2014) Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 37(6):348\u2013350. https:\/\/doi.org\/10.1097\/CJI.0000000000000041","journal-title":"J Immunother"},{"issue":"11","key":"9952_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002685","volume":"15","author":"M Warny","year":"2018","unstructured":"Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE (2018) Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med 15(11):e1002685. https:\/\/doi.org\/10.1371\/journal.pmed.1002685","journal-title":"PLoS Med"},{"issue":"1","key":"9952_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0549-5","volume":"7","author":"C M\u00e9n\u00e9trier-Caux","year":"2019","unstructured":"M\u00e9n\u00e9trier-Caux C, Ray-Coquard I, Blay JY, Caux C (2019) Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer 7(1):85. https:\/\/doi.org\/10.1186\/s40425-019-0549-5","journal-title":"J Immunother Cancer"},{"issue":"13","key":"9952_CR30","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.3390\/cancers14133282","volume":"14","author":"D Tomsitz","year":"2022","unstructured":"Tomsitz D, Schlaak M, Zierold S et al (2022) Development of lymphopenia during therapy with immune checkpoint inhibitors is associated with poor outcome in metastatic cutaneous melanoma. Cancers (Basel) 14(13):3282. https:\/\/doi.org\/10.3390\/cancers14133282","journal-title":"Cancers (Basel)"},{"issue":"5","key":"9952_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","volume":"105","author":"Y Cho","year":"2019","unstructured":"Cho Y, Park S, Byun HK et al (2019) Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 105(5):1065\u20131073. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"9952_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2668","volume":"8","author":"SM Durbin","year":"2025","unstructured":"Durbin SM, Mooradian MJ, Reynolds KL et al (2025) Late-onset immune-related adverse events after immune checkpoint inhibitor therapy. JAMA Netw Open 8(3):e252668. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.2668","journal-title":"JAMA Netw Open"},{"key":"9952_CR33","doi-asserted-by":"publisher","first-page":"1453429","DOI":"10.3389\/fphar.2024.1453429","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Li L, Tian J et al (2024) Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world FAERS analysis. Front Pharmacol 15:1453429. https:\/\/doi.org\/10.3389\/fphar.2024.1453429","journal-title":"Front Pharmacol"},{"issue":"2","key":"9952_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus MV, Alexander S, Bishop MR et al (2020) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 8(2):e001511. https:\/\/doi.org\/10.1136\/jitc-2020-001511","journal-title":"J Immunother Cancer"},{"issue":"2","key":"9952_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.annemergmed.2019.07.015","volume":"75","author":"M Shah","year":"2020","unstructured":"Shah M, Rajha E et al (2020) Adverse events of novel therapies for hematologic malignancies: what emergency physicians should know. Ann Emerg Med 75(2):264\u2013286. https:\/\/doi.org\/10.1016\/j.annemergmed.2019.07.015","journal-title":"Ann Emerg Med"},{"issue":"suppl 16","key":"9952_CR36","doi-asserted-by":"publisher","first-page":"e14684","DOI":"10.1200\/JCO.2023.41.16_suppl.e14684","volume":"41","author":"N Neupane","year":"2023","unstructured":"Neupane N, Shikhrakar S, Thapa S, Shrestha A (2023) Hemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: a pharmacovigilance study from FDA database. J Clin Oncol 41(suppl 16):e14684. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e14684","journal-title":"J Clin Oncol"},{"issue":"10","key":"9952_CR37","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","volume":"290","author":"AX Garg","year":"2003","unstructured":"Garg AX, Suri RS, Barrowman N et al (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290(10):1360\u20131370. https:\/\/doi.org\/10.1001\/jama.290.10.1360","journal-title":"JAMA"},{"key":"9952_CR38","doi-asserted-by":"publisher","DOI":"10.12703\/P6-119","volume":"6","author":"D Kavanagh","year":"2014","unstructured":"Kavanagh D, Raman S, Sheerin NS (2014) Management of hemolytic uremic syndrome. F1000Prime Rep 6:119. https:\/\/doi.org\/10.12703\/P6-119","journal-title":"F1000Prime Rep"},{"issue":"1","key":"9952_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10238-025-01688-x","volume":"25","author":"X Han","year":"2025","unstructured":"Han X, Xu J, Cui M et al (2025) Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials. Clin Exp Med 25(1):157. https:\/\/doi.org\/10.1007\/s10238-025-01688-x","journal-title":"Clin Exp Med"},{"issue":"7","key":"9952_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher K, Johnson DB (2024) Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer 12(7):e008591. https:\/\/doi.org\/10.1136\/jitc-2023-008591","journal-title":"J Immunother Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09952-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09952-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09952-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T03:39:39Z","timestamp":1760672379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09952-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9952"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09952-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"912"}}